WO2004054621A1 - Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes - Google Patents
Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes Download PDFInfo
- Publication number
- WO2004054621A1 WO2004054621A1 PCT/CN2003/000979 CN0300979W WO2004054621A1 WO 2004054621 A1 WO2004054621 A1 WO 2004054621A1 CN 0300979 W CN0300979 W CN 0300979W WO 2004054621 A1 WO2004054621 A1 WO 2004054621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ziprasidone
- cyclodextrin
- salt
- clathrate
- water
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the invention relates to a water-soluble inclusion compound of ziprasidone and a salt thereof and a preparation method thereof. Background technique
- Ziprasidone is a newer atypical antipsychotic drug. It is an antagonist of serotonin and dopamine receptors. It is effective for the symptoms of schizophrenia, including hallucinations, hallucinations, and delusions.
- the chemical name of ziprasidone 5- (2- (4- (1,2-benzoisothiazol-3-yl) -piperazine) ethyl) -6-chloro-1,3-dihydro- 2H-indole-2-one.
- FDA US Food and Drug Administration
- Geodon a muscarinic injection of ziprasidone mesylate
- Ziprasidone has a low water solubility, so it must be solubilized when preparing its injection solutions.
- the currently used solubilization technology is: firstly make ziprasidone into mesylate, and then make ziprasidone mesylate with hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl ether- ⁇ -cyclo Dextrin forms an inclusion compound in an aqueous solution to increase the water solubility of the drug, such as the technology disclosed in Chinese patent CN 97194242.0.
- the technical problem to be solved by the present invention is to disclose a water-soluble package of ziprasidone and its salt. And its preparation method to overcome the above-mentioned shortcomings of the prior art.
- the water-soluble inclusion compound of ziprasidone and its salt according to the present invention is a water-soluble inclusion compound comprising a therapeutically effective amount of the active ingredient ziprasidone and its salt and an inclusion material cyclodextrin derivative.
- the inclusion compound is said to contain no crystal water or half or more crystal water.
- the final application form of the inclusion compound is an aqueous solution, a lyophilizate, a tablet, a capsule, a granule, a pill, a suppository, or an inhalation powder.
- a preferred molar ratio of ziprasidone or a salt thereof to a cyclodextrin derivative is: 0.1 100: 1.
- the ziprasidone salt of the present invention includes mesylate, hydrochloride, benzenesulfonate, ethanesulfonate, tartrate, naphthalenesulfonate, malate, citrate, benzoate or As one of aspartate salts, the salt may be an anhydrous substance, or may be a hemihydrate or a polyhydrate.
- the cyclodextrin derivatives include a-cyclodextrin derivatives, ⁇ -cyclodextrin derivatives, and ⁇ -cyclodextrin derivatives with various degrees of substitution.
- the most ideal choice is hydroxypropyl- ⁇ -cyclodextrin.
- the method for preparing the water-soluble inclusion compound of the present invention includes the following steps:
- the organic solvent includes, but is not limited to, one or more of ethanol, methanol, acetonitrile, acetone, isopropanol, n-butanol, tetrahydrofuran, and the like.
- the inclusion compound of the present invention can be used for acute control and short-term treatment of restless mental patients, and the dosage and method of use are the same as those of conventional ziprasidone or a salt thereof.
- the preparation method of the inclusion compound of the present invention greatly shortens the time for preparing the inclusion compound, from 4 days to 2 hours, which is a kind of inclusion compound and inclusion technology with considerable practical value. detailed description
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003303019A AU2003303019A1 (en) | 2002-12-17 | 2003-11-18 | Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021551391A CN1255105C (zh) | 2002-12-17 | 2002-12-17 | 齐拉西酮及其盐的水溶性包合物及其制备方法 |
CN02155139.1 | 2002-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004054621A1 true WO2004054621A1 (fr) | 2004-07-01 |
Family
ID=4752571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000979 WO2004054621A1 (fr) | 2002-12-17 | 2003-11-18 | Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1255105C (fr) |
AU (1) | AU2003303019A1 (fr) |
WO (1) | WO2004054621A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
US7678799B2 (en) | 2003-06-03 | 2010-03-16 | Teva Pharmaceutical Industries Ltd. | Crystalline ziprasidone HCl and processes for preparation thereof |
US7745624B2 (en) | 2005-03-11 | 2010-06-29 | Apotex Pharma Chem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
WO2011148253A2 (fr) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Formes posologiques solides d'antipsychotiques |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100391458C (zh) * | 2006-02-07 | 2008-06-04 | 上海医药工业研究院 | 齐拉西酮或其盐包合物制备方法 |
CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1083061A (zh) * | 1992-08-26 | 1994-03-02 | 美国辉瑞有限公司 | 制备芳基哌嗪基-杂环化合物的方法 |
CN1089607A (zh) * | 1992-09-01 | 1994-07-20 | 美国辉瑞有限公司 | 5-(2-(4-(1,2-苯并异噻唑-3-基)-1-哌嗪基)乙基)-6-氟-1,3-二氢-2h-吲哚-2-酮盐酸盐一水合物 |
CN1136776A (zh) * | 1993-09-30 | 1996-11-27 | 詹森药业有限公司 | 一种抗真菌口服制剂 |
CN1216923A (zh) * | 1996-05-07 | 1999-05-19 | 美国辉瑞有限公司 | 芳基杂环化合物盐的包合复合物 |
-
2002
- 2002-12-17 CN CNB021551391A patent/CN1255105C/zh not_active Expired - Fee Related
-
2003
- 2003-11-18 WO PCT/CN2003/000979 patent/WO2004054621A1/fr not_active Application Discontinuation
- 2003-11-18 AU AU2003303019A patent/AU2003303019A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1083061A (zh) * | 1992-08-26 | 1994-03-02 | 美国辉瑞有限公司 | 制备芳基哌嗪基-杂环化合物的方法 |
CN1089607A (zh) * | 1992-09-01 | 1994-07-20 | 美国辉瑞有限公司 | 5-(2-(4-(1,2-苯并异噻唑-3-基)-1-哌嗪基)乙基)-6-氟-1,3-二氢-2h-吲哚-2-酮盐酸盐一水合物 |
CN1136776A (zh) * | 1993-09-30 | 1996-11-27 | 詹森药业有限公司 | 一种抗真菌口服制剂 |
CN1216923A (zh) * | 1996-05-07 | 1999-05-19 | 美国辉瑞有限公司 | 芳基杂环化合物盐的包合复合物 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678799B2 (en) | 2003-06-03 | 2010-03-16 | Teva Pharmaceutical Industries Ltd. | Crystalline ziprasidone HCl and processes for preparation thereof |
US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
US7745624B2 (en) | 2005-03-11 | 2010-06-29 | Apotex Pharma Chem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
WO2011148253A2 (fr) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Formes posologiques solides d'antipsychotiques |
Also Published As
Publication number | Publication date |
---|---|
CN1424037A (zh) | 2003-06-18 |
AU2003303019A1 (en) | 2004-07-09 |
CN1255105C (zh) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175288B1 (da) | Farmaceutiske midler indeholdende lægemidler, der er ustabile eller sparsomt oplöselige i vand, og fremgangsmåder til deres fremstilling | |
JPS61275301A (ja) | r−シクロデキストリン誘導体 | |
PL189324B1 (pl) | Środek farmaceutyczny i nowe sole zyprazydonu | |
TW200930712A (en) | The amorphous of a heterocyclic compound, the solid dispersoid consisting it, the preparation, and the process for preparing thereof | |
WO2012019381A1 (fr) | Composition pharmaceutique orale contenant une inclusion d'édaravone et d'une cyclodextrine et son procédé de préparation | |
US20070111965A1 (en) | Compositions comprising lipoxygenase inhibitors and cyclodextrin | |
US20090275622A1 (en) | Nizatidine formulations | |
JP2014515359A (ja) | ベンズイミダゾール誘導体を含む固形医薬組成物 | |
CN110876259B (zh) | 注射用组合物 | |
WO2015001133A1 (fr) | Composition pharmaceutique comprenant de l'ivabradine amorphe | |
ES2149750T3 (es) | Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos. | |
WO2004054621A1 (fr) | Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes | |
AU2017313897B2 (en) | Pharmaceutical composition and methods of uses | |
WO2016097011A1 (fr) | Composition pharmaceutique comprenant de l'agomélatine amorphe | |
US5403840A (en) | Inclusion complexes of N-ethoxycarbonyl 1-3-morpholino-sydnonimine or salts formed with cyclodextrin-derivatives, preparation thereof and pharmaceutical compositions containing the same | |
CZ20031490A3 (cs) | Fyzikální směsi a inkluzní komplexy obsahující torasemid a cyklodextriny nebo cyklodextrinové deriváty, způsoby jejich výroby a farmaceutické formy je obsahující | |
WO2017107894A1 (fr) | Composé d'inclusion de médicament, composition à base de celui-ci et leur procédé de préparation | |
WO2004089338A1 (fr) | Clathrate a base d'arbidol, son procede de preparation et son utilisation | |
CN103351342B (zh) | 一种依达拉奉药物共晶及其制备方法 | |
JP2005531577A (ja) | ロジグリタゾン包接複合体 | |
WO2024002147A1 (fr) | Complexe d'inclusion de cyclodextrine et d'un dérivé de quinoléine ou d'un sel de celui-ci | |
JP2017518354A (ja) | 感染症を治療するための方法 | |
WO2018133009A1 (fr) | Composition de fumarate de vonoprazan et sa méthode de préparation | |
CN112826944A (zh) | 一种安立生坦包合物及其制备方法 | |
JP2020019731A (ja) | アムロジピンベシル酸塩の苦味抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |